A little-known Chinese company has made a drug that beats the world's biggest-selling medicine, said a CNN report on ...

Merck (NYSE:MRK) shares snaps six straight sessions of gains, as the stock closed 2.2% lower at $89.38 on Wednesday. The ...

We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

GenBioPro, the largest manufacturer of abortion pills in the U.S., is wading into a federal court case over abortion access ...

Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Receiving Fast Track designation for PYX-201 from the FDA marks a significant milestone for Pyxis Oncology, recognizing our potential to address the significant medical need in R/M HNSCC. This ...

The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of ...

Merck warns Keytruda faces IRA price cuts from 2028, alongside patent expiry and biosimilar competition. Drug hit $29.5B ...

For decades, researchers have worked to create drugs that teach the immune system to kill cancer cells the way traditional ...